$8.49 -$0.18 (-2.1%)

04:00 PM EDT on 08/23/19

Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

CAPS Rating: 3 out of 5

Current Price $8.49 Mkt Cap $516.1M
Open $8.64 P/E Ratio 0.00
Prev. Close $8.67 Div. (Yield) $0.00 (0.0%)
Daily Range $8.47 - $8.76 Volume 494,015
52-Wk Range $7.41 - $15.00 Avg. Daily Vol. 22

Caps

How do you think NASDAQ:ITCI will perform against the market?

Add Stock to CAPS Watchlist

All Players

33 Outperform
5 Underperform
 

All-Star Players

12 Outperform
3 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top NASDAQ:ITCI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.84)
Submitted January 12, 2016

I like Intra-Cellular's position despite the recent massive pullback. After strong enough phase III data from the first schizophrenia trial to support FDA approval, data from the second phase III trial is expected in mid 2016. The company has also… More

stockgripes (99.30)
Submitted September 16, 2015

I say for short term it will loose 25% value

NASDAQ:ITCI VS S&P 500 (SPY)

NASDAQ:ITCI Summary

Fools bullish on NASDAQ:ITCI are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ITCI.

Recs

0
Member Avatar OklaBoston (< 20) Submitted: 8/15/2019 4:26:47 PM : Outperform Start Price: $9.03 NASDAQ:ITCI Score: -5.29

Rising insider ownership primarily. Improving technicals help.

Recs

0
Member Avatar LifeScientist (28.23) Submitted: 2/17/2016 2:37:17 PM : Outperform Start Price: $30.57 NASDAQ:ITCI Score: -119.61

watch 27 is an entry

Recs

1
Member Avatar zzlangerhans (99.84) Submitted: 1/12/2016 1:28:49 AM : Outperform Start Price: $48.78 NASDAQ:ITCI Score: -126.35

I like Intra-Cellular's position despite the recent massive pullback. After strong enough phase III data from the first schizophrenia trial to support FDA approval, data from the second phase III trial is expected in mid 2016. The company has also initiated two phase III trials in bipolar depression. Meanwhile, there was 510M in the bank at the end of Q3 thanks to a huge financing in September. Intra-Cellular has been vulnerable to broad sector declines previously and bounced back strongly. We've never added to our small 150 share zzporte position but it looks like the time has finally arrived.

Leaderboard

Find the members with the highest scoring picks in ITCI.

Score Leader

km00nster

km00nster (< 20) Score: +175.29

The Score Leader is the player with the highest score across all their picks in ITCI.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. km00nster < 20 9/21/2015 Underperform 5Y $50.63 -83.23% +45.24% +128.47 1 Comment
Hendrickson71 < 20 1/7/2016 Underperform 3W $48.05 -82.33% +45.73% +128.06 1 Comment
stockgripes 99.30 9/16/2015 Underperform 5Y $45.15 -81.20% +42.54% +123.73 1 Comment
acekeldog 99.70 6/14/2017 1/29/2019 Underperform 1Y $10.71 -20.73% +16.51% +37.23 0 Comment
OklaBoston < 20 8/16/2019 Outperform 3Y $9.03 -5.98% -0.69% -5.29 1 Comment
cruisin25 26.38 7/9/2019 Outperform 3M $11.42 -25.66% -4.05% -21.61 0 Comment
allforone 28.69 7/22/2019 Outperform 1Y $11.45 -25.85% -4.20% -21.65 0 Comment
drugtrader 90.03 10/11/2018 Outperform 5Y $18.44 -53.96% +2.74% -56.69 0 Comment
derbydog85 < 20 12/23/2016 Outperform 5Y $15.62 -45.65% +26.25% -71.89 0 Comment
beecha < 20 9/11/2017 Outperform 5Y $21.66 -60.80% +14.76% -75.57 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 86.36 5/2/2016 Underperform 3W $35.08 -75.80% +36.88% +112.67 0 Comment